Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy

Sep 15, 2017 | Magazine: Clinical Cancer Research

Pérez-Ruiz E (1,2,3), Etxeberria I (1,2), Rodriguez-Ruiz ME (1,2,4,5), Melero I (6,2,4,5).

ABSTRACT

T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models.

Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.

CITATION Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.

see publication in pubmed

Our authors

Imagen de la Dra. Esperanza Rodríguez Ruiz, especialista en oncología radioterápica de la Clínica Universidad de Navarra

Dr. María Rodríguez Ruiz [SP] Curriculum

Clinical Researcher Immunology and Immunotherapy Research Program

Imagen Dr. Ignacio Melero Bermejo, Inmunología

Dr. Ignacio Melero Bermejo Curriculum

Senior Researcher | Principal Investigator Immunology and Immunotherapy Research Program